Spots Global Cancer Trial Database for Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer
Official Title: A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer
Study ID: NCT00912444
Conditions
Study Description
Brief Summary: The purpose of this study is to compare the pathological complete response (pCR) rate in triple-negative or Her2 positive breast cancer patients treated with neoadjuvant docetaxel, anthracycline and cyclophosphamide (TAC) or docetaxel and cyclophosphamide (TC) regimen.
Detailed Description: Breast cancer is the leading cause of cancer in women in China. Neoadjuvant chemotherapy for treatment of locally advanced breast cancer has become a standard therapy. Results from neoadjuvant trials have shown that pathological complete response (pCR) is an independent predictor of outcome. Docetaxel was introduced into clinical practice in the early 1990s and has demonstrated good activity in the adjuvant and metastatic settings. Both TC and TAC are effective regimens in the adjuvant setting. The most optimal regimen in the neoadjuvant treatment is however unknown. This is especially true in triple-negative or HER2 positive breast cancer. This study will evaluate the pCR rate of TAC and TC as neoadjuvant treatment for triple-negative or HER2 positive breast cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
The First People's Hospital of Foshan, Foshan, Guangdong, China
Guangdong Provincial Maternal and Child Health Hospital, Guangzhou, Guangdong, China
Guangzhou General Hospital of Guangzhou Military Area, Guangzhou, Guangdong, China
Xiangya Hospital Central South University, Changsha, Hunan, China
Hunan Cancer Hospital, Changsha, Hunan, China
Jiangyin People's Hospital, Jiangyin, Jiangsu, China
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
The Second Affilliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Wujiang First People's Hospital, Wujiang, Jiangsu, China
The third hospital of Nanchang, Nanchang, Jiangxi, China
Linyi People's Hospital, Linyi, Shandong, China
Shanghai Obstetrics and Gynecology Hospital, Shanghai, Shanghai, China
Ruijin Hospital, Shanghai, Shanghai, China
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
the International Peace Maternity and Child health Hospital, Shanghai, Shanghai, China
Xin Hua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Shanxi Provincical Cancer Hospital, Taiyuan, Shanxi, China
Fisrt Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Shanxi, China
West China Hospital Sichuan University, Chengdu, Sichuan, China
Sinkiang Uygur Autonomous Region Cancer Hospital, Urumqi, Xinjiang, China
Yunnan Provincical Tumor Hospital, Kunming, Yunnan, China
Obstetrics and Gynecology Hospital affiliated to Zhejiang University, Hangzhou, Zhejiang, China
Zhejiang Traditional Chinese Medical Hospital, Hangzhou, Zhejiang, China
Ningbo First People's Hospital, Ningbo, Zhejiang, China
Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China
The First Affilliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China
Ruian People's Hospital, Wenzhou, Zhejiang, China
Contact Details
Name: Kunwei Shen
Affiliation: Shanghai Jiao Tong University School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
